Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FPR2 | P25090 | 5/20 | 0.49 |
| ▸ | FPR1 | P21462 | 2/20 | 0.49 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.45 |
| ▸ | F10 | P00742 | 2/20 | 0.45 |
| ▸ | GPR119 | Q8TDV5 | 1/20 | 0.42 |
| ▸ | ALOX5AP | P20292 | 9/20 | 0.42 |
| ▸ | FEN1 | P39748 | 9/20 | 0.42 |
| ▸ | POLB | P06746 | 1/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.40 |
| ▸ | TSHR | P16473 | 1/20 | 0.40 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6988775 | 0.86 | FPR2 (0.48) | FPR2FPR1GPR119ALOX5APFEN1 | |
| SCHEMBL7065465 | 0.81 | FPR2 (0.53) | FPR2FPR1L3MBTL1F10GPR119 | |
| SCHEMBL7065460 | 0.81 | FPR2 (0.53) | FPR2FPR1L3MBTL1F10GPR119 | |
| SCHEMBL7064874 | 0.80 | FPR2 (0.48) | FPR2FPR1L3MBTL1F10GPR119 | |
| SCHEMBL7065471 | 0.79 | FPR2 (0.48) | FPR2FPR1F10GPR119 | |
| SCHEMBL7064681 | 0.79 | PRSS1 (0.50) | FPR2FPR1F10 | |
| SCHEMBL7065095 | 0.79 | FPR2 (0.48) | FPR2FPR1F10GPR119 | |
| SCHEMBL7065504 | 0.78 | FPR2 (0.46) | FPR2FPR1F10GPR119ALOX5AP | |
| SCHEMBL7065509 | 0.78 | FPR2 (0.46) | FPR2FPR1F10GPR119ALOX5AP | |
| SCHEMBL7062039 | 0.77 | F10 (0.49) | FPR2FPR1F10 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20030176465-A1 | Cyclic amino acid derivatives | MERCK PATENT GMBH (DE) | 2003-09-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030176465-A1 | Cyclic amino acid derivatives | F5, F11, F2 | FPR2 27/4885FPR1 10/4885L3MBTL1 1902/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.